Actively Recruiting
Exploratory Study Evaluating Safety and Effects of IVB103 Injection in Adults with Neovascular Wet Age-Related Macular Degeneration
Led by InnoVec Biotherapeutics Inc. · Updated on 2026-11-04
18
Participants Needed
1
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of IVB103 injection in people with neovascular wet age-related macular degeneration nAMD. This early phase 1 study is open-label, meaning participants and researchers know the treatment being given, and it is conducted across multiple centers. The goal is to understand how well different doses of IVB103 work and how safe they are for treating this eye condition. Participants will receive a single injection of IVB103 directly into one eye via an intravitreal injection. There are three dosing groups low, intermediate, and high dose, and participants will be assigned sequentially to one of these doses. After the injection, participants will be monitored closely for up to 52 weeks, with the option for continued follow-up for up to five years to further assess long-term safety and effects. Throughout the study, participants will undergo assessments including visual function tests and OCT imaging to evaluate eye health and response to treatment. Researchers will track any adverse events and serious adverse events for safety. The study will also record the need for other anti-VEGF treatments during the follow-up period. Participants involvement can last several years, with regular visits and monitoring to gather comprehensive data on the treatments impact and tolerability.
CONDITIONS
Brief Title
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Research Team
C
Cheng Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here